NCT06678048View on ClinicalTrials.gov

Arsenous Acid for Refractory Triple-Negative Breast Cancer

PHASE2RecruitingINTERVENTIONAL
Enrollment

12

Participants

Timeline

Start Date

October 23, 2024

Primary Completion Date

April 22, 2026

Study Completion Date

October 23, 2026

Conditions
Breast Cancer
Interventions
DRUG

Arsenous Acid plus Chemotherapy

Arsenous Acid , Eribulin, Gemcitabine, Utidelone, Vinorelbine

Trial Locations (1)

510060

RECRUITING

Sun Yat-sen University Cancer Center, Guangzhou

All Listed Sponsors
lead

Sun Yat-sen University

OTHER